The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

zebrabiologics.com

Stage

Unattributed VC | Dead

Total Raised

$12M

Last Raised

$3M

About Zebra Biologics

Zebra Biologics was founded in July 2013 by scientists in antibody engineering, experienced biotech executives and private investors. Zebra will take advantage of new technologies developed by Dr Richard Lerner and colleagues at the The Scripps Research Institute in San Diego, to generate both agonist and antagonist antibody for a wide array of therapeutic applications. Zebra has obtained an exclusive license to these technologies and plans to enter into major R&D collaborative with pharmaceutical and biotechnology companies to bring a portfolio of "bio-superiors" antibodies into clinical development within the next 2-5 years.

Zebra Biologics Headquarter Location

1041 Old Marlboro Road

Concord, Massachusetts, 01742,

United States

978-505-8719

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Zebra Biologics Patents

Zebra Biologics has filed 2 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/2/2017

4/13/2021

Monoclonal antibodies, Proteins, Immune system, Clusters of differentiation, Immunology

Grant

Application Date

5/2/2017

Grant Date

4/13/2021

Title

Related Topics

Monoclonal antibodies, Proteins, Immune system, Clusters of differentiation, Immunology

Status

Grant

Latest Zebra Biologics News

Zebra Biologics to Collaborate with AbbVie

Jan 10, 2017

Zebra Biologics to Collaborate with AbbVie 1/9/17 CONCORD, Mass.--( BUSINESS WIRE )--Zebra Biologics Inc., an emerging pre-clinical stage biotechnology company, today announced that the company has entered into a collaboration with AbbVie to discover agonist antibody therapeutics for inflammatory diseases. Zebra will use its novel and patented function-based antibody discovery platform to generate antibodies that activate biological pathways associated with targets designated by AbbVie. Zebra and AbbVie will collaborate closely on the identification and pre-clinical evaluation of emerging candidates. The targets were not disclosed. Under the terms of the agreement, Zebra will lead the discovery of candidate agonist antibodies for designated targets and will collaborate with AbbVie in pre-clinical validation of select clinical candidates. Upon advancement of clinical candidates, AbbVie would be responsible for clinical development, manufacturing, regulatory approval and world-wide commercialization. Financial terms were not disclosed. “This collaboration is an important step in the evolution of Zebra from an early stage discovery company toward our vision of developing ground breaking biologic drug therapies for many serious medical conditions,” said Ronald M. Lindsay, PhD., Chairman & Chief Executive Officer at Zebra. “Since inception in 2013, we have focused on expanding the application of Zebra’s core technology to multiples types of drug targets across a broad spectrum of therapeutic areas. We are now very pleased to enter into a significant collaboration with AbbVie, the world’s leader in developing biologic therapies for painful and debilitating inflammatory diseases.” About Agonist Antibodies To date all clinically approved antibody therapeutics exert their effect by blocking (antagonizing) signaling between ligands and receptors or by neutralizing pathogens. Rare antibody molecules may also activate biochemical pathways, although finding such “agonist” antibodies has proven difficult. As demonstrated in key peer-reviewed publications, the recently developed Zebra screening platform opens up a novel biological function-based approach to screening very large combinatorial antibody or other peptidic libraries for potent and highly selective agonist biologic drugs. About Zebra Biologics Zebra is a privately held pre-clinical stage biopharmaceutical company. The Company is pioneering the development of platform technologies that allow cellular function-based screening for the discovery and selection of fully human therapeutic biologics (antibodies, peptides or proteins) from DNA-encoded combinatorial libraries of human antibodies, peptides or “protein-in-proteins”. Applicable for lead discovery across all therapeutic areas and all receptor classes, Zebra has optimized the platform for the highly desirable feature of allowing selection of rare agonist antibodies from very large combinatorial libraries.

  • Where is Zebra Biologics's headquarters?

    Zebra Biologics's headquarters is located at 1041 Old Marlboro Road, Concord.

  • What is Zebra Biologics's latest funding round?

    Zebra Biologics's latest funding round is Unattributed VC.

  • How much did Zebra Biologics raise?

    Zebra Biologics raised a total of $12M.

  • Who are the investors of Zebra Biologics?

    Investors of Zebra Biologics include Frost Group and OPKO Health.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.